Given the potent role of DCs in T cell activation against tumor cells, we hypothesized that NF-κB2 deficiency in DCs renders antigen-presenting cells (APCs) better able to activate T cells for lung cancer suppression. This evidence concerns the gene NFKB2 and neoplasm.